IGEA Pharma N.V. IGEA to get SIX approval to the semi-annual 2022 report disclosure
IGEA Pharma N.V. / Key word(s): Annual Results/Annual Results
IGEA to get SIX approval to the semi-annual 2022 report disclosure
Hoofddorp, the Netherlands, 30 September 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the half year 2022 report.
In accordance with our statutory auditors, considering that we will publish the 2021 annual report in the next days, it will be unusual to publish the half year 2022 report before the publication of the 2021 annual report.
In accordance with SIX’s approval, this press release sets out the relevant section of the decision:
“I. The exemption application of IGEA (Issuer) dated 29 September 2022 requesting an
extension of the deadline to publish its semi-annual 2022 annual report and to file such report with SIX Exchange Regulation AG until 31 October 2022 at the latest is granted with the following reservation (lit. a and b) and under the following conditions (lit. c):
- SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2022 semi-annual report is not published in accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the Directive on Ad hoc Publicity [DAH]) and not filed with SIX Exchange Regulation AG until Monday, 31 October 2022, 11.59 pm CET, at the latest.